Solteq’s Q4 results were weak and below our expectations, with revenue at EUR 16.
Redeye returns with an updated take on the pick-and-shovel play Genovis following its partner Select...
The go-to-market strategy is now implemented following the split with Thermo Fisher during the quart...
Redeye sees another powerful Q4 report. The sales were considerably higher than expected, with an op...
Redeye states that the quarterly financials were better than expectations, and we expect to adjust o...
Adj. EBITDA SEK 5.4m vs. ABGSCe 0.2m Circular Energy very strong at SEK 38m sales (ABGSCe 18m) 12-6x...
Starbreeze reported net sales in Q4 of SEK33.6m was in line with our estimate of SEK34.
Redeye strengthens its positive view of CombinedX following a robust Q4 report with strong organic g...
Q4 well above our expectations, mainly on margins Weak CF, but driven by the "right" reasons Share i...
ARR +10% y-o-y, +3% vs ABGSCe Cons. likely to make pos.
Redeye saw sales that almost reached our expectations for the quarter.
Mestro reported a strong quarter with accelerating growth numbers underpinned by some larger contrac...
Redeye will likely raise its Base Case and forecasts following a solid report where strong growth in...
EBITDA SEK 52m vs. ABGSCe SEK 66m Average realized price of SEK 850/MWh vs.
Redeye states that Doro’s Q4 22022 report was better than expected
Redeye's first comments on the Q4 report this morning.
Redeye argues that Safeture’s Q4 2022 report was rather undramatic, although it was hit by a one-tim...
Wants to implement licensing model for Functional Wood Cash position still slim at SEK 15m, but up f...
Redeye updates its view on M.O.B.A. Network following its Q4 2022 report.
Redeye provides an initial take on Sedana Medical’s Q4 results, and we are optimistic about the sale...
